Beyfortus® Immunization: Protecting Infants from RSV
Monday, Oct 28, 2024 6:03 pm ET
1min read The recent approval and distribution of Beyfortus® (nirsevimab-alip) 50mg and 100mg Injection doses in the US marks a significant milestone in the prevention of respiratory syncytial virus (RSV) disease in infants. Sanofi, in collaboration with AstraZeneca, has taken steps to ensure the majority of doses are available ahead of the RSV season, aiming to provide access to immunization for every eligible baby.
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. Two out of three infants are infected with RSV during their first year of life, and almost all children are infected by their second birthday. Most of the time, RSV will cause a mild, cold-like illness. However, in some cases, it can lead to severe lower respiratory tract disease, requiring hospitalization. Beyfortus® is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
The approval of Beyfortus® by the U.S. Food and Drug Administration (FDA) expands manufacturing capacity and helps meet demand. With the recent approval of a new filling line for Beyfortus®, doses are now ready to ship, expanding supply for the Northern Hemisphere ahead of the 2024/2025 RSV season (November – March). Another filling line is expected to provide doses for the 2024/2025 season, adding additional production capacity. Sanofi continues to work with AstraZeneca to build inventory for this and future seasons.
Sanofi also took additional measures to ensure greater readiness for this season by launching the Beyfortus® Reservation Program, which provides critical insight on private healthcare provider demand and allows for prioritized fulfillment of requests placed through the program. The company also continues to collaborate with government agencies, including the White House's Office of Pandemic Preparedness and Response Policy, to ensure readiness.
Private customers interested in ordering Beyfortus® doses should contact their Sanofi representative or request a representative at BEYFORTUS.com.
The approval and distribution of Beyfortus® highlight the commitment of Sanofi and AstraZeneca to protect infants from RSV disease. With the upcoming RSV season, Beyfortus® offers its demonstrated real-world protection to as many infants as possible, contributing to the goal of equitable access to immunization.
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. Two out of three infants are infected with RSV during their first year of life, and almost all children are infected by their second birthday. Most of the time, RSV will cause a mild, cold-like illness. However, in some cases, it can lead to severe lower respiratory tract disease, requiring hospitalization. Beyfortus® is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
The approval of Beyfortus® by the U.S. Food and Drug Administration (FDA) expands manufacturing capacity and helps meet demand. With the recent approval of a new filling line for Beyfortus®, doses are now ready to ship, expanding supply for the Northern Hemisphere ahead of the 2024/2025 RSV season (November – March). Another filling line is expected to provide doses for the 2024/2025 season, adding additional production capacity. Sanofi continues to work with AstraZeneca to build inventory for this and future seasons.
Sanofi also took additional measures to ensure greater readiness for this season by launching the Beyfortus® Reservation Program, which provides critical insight on private healthcare provider demand and allows for prioritized fulfillment of requests placed through the program. The company also continues to collaborate with government agencies, including the White House's Office of Pandemic Preparedness and Response Policy, to ensure readiness.
Private customers interested in ordering Beyfortus® doses should contact their Sanofi representative or request a representative at BEYFORTUS.com.
The approval and distribution of Beyfortus® highlight the commitment of Sanofi and AstraZeneca to protect infants from RSV disease. With the upcoming RSV season, Beyfortus® offers its demonstrated real-world protection to as many infants as possible, contributing to the goal of equitable access to immunization.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
_cbf77e8c1748017079428.jpeg)
